Get started
Author

David Humberto Marmolejo Castañeda

Observed names: D. Marmolejo Castaneda, D.H. Marmolejo Castaneda
ORCID: 0000-0003-0863-1440
Observed ORCID: 0000-0003-0863-1440
OpenAlex ID: A5035381175
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
2022 · Kreina Sharela Vega Cano, David Humberto Marmolejo Castañeda, et al. · Cancers · 26
PDF
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.
2023 · Giacomo Nuvola, David Humberto Marmolejo Castañeda, et al. · Journal of Clinical Oncology · 4
A case of Rothmund-Thomson syndrome originally thought to be a case of Bloom syndrome
2022 · David Humberto Marmolejo Castañeda, Mara Cruellas Lapeña, et al. · Familial Cancer · 4
Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI).
2024 · Dimitra Rafailia Bakaloudi, Rafee Talukder, et al. · Journal of Clinical Oncology · 2
1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations
2020 · A. Garcia-Alvarez, H. Verdaguer, et al. · Annals of Oncology · 2
493P The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
2024 · K. Vega Cano, J. Garre, et al. · Annals of Oncology · 1
PDF
Site of metastasis and clinical outcomes in patients with advanced renal cell carcinoma treated with TKI monotherapy or combination therapy: A real-world analysis.
2024 · Giacomo Nuvola, Victor Navarro, et al. · Journal of Clinical Oncology · 1
1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
2021 · O. Mirallas, D. López-Valbuena, et al. · Annals of Oncology · 1
PDF
1186P Impact of temozolomide (TEM) and capecitabine (CAP) dose reductions in toxicity and efficacy in patients (pts) with neuroendocrine neoplasms (NENs) treated with CAPTEM chemotherapy
2020 · J. Hernando, A. Garcia-Alvarez, et al. · Annals of Oncology · 1
1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital
2020 · D. García-Illescas, N. Saoudi Gonzalez, et al. · Annals of Oncology · 1
PDF
Prognosis of patients (pts) with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma (la/mUC).
2026 · Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al. · Journal of Clinical Oncology
2410P A ten-year perspective on Radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): Survival, symptom control, and lessons learned
2025 · J.R. Staufert Gutierrez, J. Echeverri, et al. · Annals of Oncology
1041P Prognostic impact of embryonal and yolk sac components in metastatic NSGCT—insights from a multinational retrospective cohort
2025 · M. Pedregal Trujillo, I. Miras Rodriguez, et al. · Annals of Oncology
Survival outcomes of patients with mNSGCTs with and without teratoma in the primary tumor: An international retrospective study.
2025 · Manuel Pedregal, Begoña P. Valderrama, et al. · Journal of Clinical Oncology
Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays.
2024 · Pablo Cresta Morgado, Sara Arce-Gallego, et al. · Journal of Clinical Oncology
Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).
2024 · Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al. · Journal of Clinical Oncology
PDF
Impact of maximal transurethral resection of bladder tumor before neoadjuvant chemotherapy for muscle-invasive bladder cancer
2022 · D.H. Marmolejo Castaneda, R. Morales-Barrera, et al. · European Urology Open Science
686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
2022 · O. Mirallas, D.H. Marmolejo Castaneda, et al. · Annals of Oncology
1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
2021 · S. Cedres, J.D. Assaf, et al. · Annals of Oncology
Analysis of chemotherapy efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p).
2021 · Susana Cedres Perez, Juan David Assaf Pastrana, et al. · Journal of Clinical Oncology
938P Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
2020 · A. Hernando-Calvo, O. Mirallas, et al. · Annals of Oncology
1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients
2020 · D.A. Acosta Eyzaguirre, H. Verdaguer, et al. · Annals of Oncology
PDF
499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer
2020 · I. Baraibar Argota, C. Rubio-Pérez, et al. · Annals of Oncology
PDF
Works count: 23
Citation count: 43
H-index: 3
I10-index: 1
Year
Topic
Type